Priority 16 from the Mesothelioma PSP
| UNCERTAINTY: Should treatment for mesothelioma, if the patient has no symptoms, be given immediately or delayed? (JLA PSP Priority 16) | |
|---|---|
| Overall ranking | 16 |
| JLA question ID | 0025/16 |
| Explanatory note | Not available for this PSP |
| Evidence | Ongoing study - A multicentre non-blinded randomised controlled trial to assess the impact of Regular Early SPEcialist symptom Control Treatment on quality of life in malignant Mesothelioma - “RESPECT-Meso” |
| Health Research Classification System category | Cancer |
| Extra information provided by this PSP | |
|---|---|
| Original uncertainty examples | Would like to see trial of early vs delayed treatments in asymptomatic/minimally symptomatic pts repeated. There was a 50:50 split last time I saw it debated - which implies we really don't know the best answer ~ Chemotherapy was the only treatment on offer (though not needed as yet) |
| Comparison | Drug |
| Submitted by | Health Professional ~ Patient |
| Outcomes to be measured | Survival and Quality of Life |
| PSP information | |
|---|---|
| PSP unique ID | 0025 |
| PSP name | Mesothelioma |
| Total number of uncertainties identified by this PSP. | 53 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website) |
| Date of priority setting workshop | 16 December 2014 |